Jump to content

Bradanicline

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by BsherrAWBBOT (talk | contribs) at 22:15, 28 July 2020 (orphaning per Wikipedia:Templates for discussion/Log/2020 July 17#Template:Nootropics, plus general fixes). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Bradanicline
Clinical data
Other namesTC-5619
Identifiers
  • N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.445 g·mol−1
3D model (JSmol)
  • C1CN2CCC1[C@@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
  (verify)

Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.[2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[7] It was also discontinued for ADHD, and no longer seems to be being developed.[7]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
  2. ^ TC-5619 Cognitive Dysfunction in Schizophrenia Archived August 20, 2008, at the Wayback Machine
  3. ^ Rethinking Schizophrenia
  4. ^ Targacept retains full development rights for TC-5619
  5. ^ Targacept ends development of ADHD drug
  6. ^ "Statement on a Nonproprietary Name Adopted by the USAN Council" (Document). November 27, 2013. {{cite document}}: Cite document requires |publisher= (help); Unknown parameter |url= ignored (help)
  7. ^ a b "Bradanicline - Attenua - AdisInsight".


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bradanicline&oldid=970044811"